Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55fa76c9b7175910a5bffb3e26fb5b2a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
filingDate |
2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_168bf40a1380e89ddcbc9e5d825b07f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b08fa9a9b671863cbdcf173120129d3 |
publicationDate |
2022-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3983079-A1 |
titleOfInvention |
Pharmaceutical formulations of bi-specific diabodies and use of the same |
abstract |
The present invention is directed to stable aqueous pharmaceutical formulations that comprise a bispecific monovalent diabody ("Diabody formulation"), and to aqueous stabilizer solutions for stabilizing and administering said diabody. The invention particularly concerns such pharmaceutical formulations that comprise a diabody drug product (DART- A DP formulations) that comprise a sequence-optimized CD 123 x CDS bispecific diabody (DART- A) that is capable of simultaneously binding to CD 123 and CDS. The invention further concerns the use of such DART- A DP formulations in the treatment of hematologic malignancies such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients. |
priorityDate |
2019-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |